Does Affinity Health Plan Cover Dupixent?

Affinity Health Plan and Its Transition to Molina Healthcare

Affinity Health Plan was a nonprofit Medicaid managed care organization based in the Bronx, New York, serving over 280,000 members across New York City and surrounding counties. In 2014, Molina Healthcare acquired Affinity Health Plan and absorbed its membership into Molina Healthcare of New York.

What This Means for Current Members

If you enrolled through Affinity Health Plan, your coverage is now administered by Molina Healthcare of New York. Formulary decisions, prior authorization requirements, and appeals processes all follow Molina's policies. Your member ID card should reflect the Molina branding, and Molina's pharmacy benefit team handles all specialty drug requests, including Dupixent.

Checking Your Current Formulary

Molina Healthcare of New York publishes its formulary annually with quarterly updates. Dupixent appears on the specialty tier for both Medicaid managed care and Health Insurance Marketplace plans offered through the NY State of Health exchange. You can verify your specific formulary by logging into the Molina member portal or calling the number on the back of your ID card.

How Dupixent Works and What the FDA Has Approved

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by binding the IL-4 receptor alpha subunit. These two cytokines are central drivers of type 2 inflammation, which underlies several chronic conditions affecting the skin, lungs, and gastrointestinal tract [1].

FDA-Approved Indications

The FDA has approved Dupixent for six indications as of 2024: moderate-to-severe atopic dermatitis (ages 6 months and older), moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependence (ages 6 and older), chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, eosinophilic esophagitis (EoE) in patients weighing 40 kg or more, prurigo nodularis in adults, and chronic obstructive pulmonary disease (COPD) with type 2 inflammation in adults [2].

Key Clinical Evidence for Atopic Dermatitis

In the SOLO 1 and SOLO 2 trials (N=1,379 combined), dupilumab 300 mg every two weeks produced an IGA score of 0 or 1 in 36 to 38% of patients at 16 weeks, compared with 8 to 10% for placebo [3]. The LIBERTY AD CHRONOS trial (N=740) showed that dupilumab combined with topical corticosteroids achieved EASI-75 in 69% of patients at 52 weeks versus 23% with placebo plus topical corticosteroids [4].

For pediatric patients aged 6 months to 5 years, the phase 3 trial (N=162) demonstrated EASI-75 in 53% of dupilumab-treated patients versus 11% on placebo at 16 weeks [5].

Prior Authorization Requirements for Dupixent

Nearly all insurance plans, including Molina Healthcare of New York (formerly Affinity), require prior authorization before covering Dupixent. This is standard for specialty biologics with annual costs exceeding $40,000.

Typical Documentation Your Provider Must Submit

Your prescribing physician will need to provide several pieces of information to Molina's pharmacy benefit manager. The request should include a confirmed diagnosis by a dermatologist or allergist, documentation of disease severity (such as an IGA score of 3 or 4, or body surface area involvement exceeding 10%), and records showing an inadequate response to or intolerance of conventional therapies.

Step Therapy Requirements

Molina Healthcare of New York generally requires evidence that the patient has tried and failed at least one of the following before approving Dupixent for atopic dermatitis:

• High-potency topical corticosteroids used for a minimum of 4 weeks
• Topical calcineurin inhibitors (tacrolimus or pimecrolimus)
• Systemic immunosuppressants such as cyclosporine, methotrexate, or mycophenolate mofetil

For asthma indications, step therapy typically requires documented failure of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA) combination, and blood eosinophil counts of 150 cells/μL or higher [6].

Timeline for Approval

Standard prior authorization decisions under New York Medicaid must be completed within 3 business days of receiving a complete request. Expedited reviews for urgent clinical situations must be completed within 24 hours. If approved, the authorization typically lasts 12 months before renewal is required.

Cost of Dupixent Under Molina Healthcare of New York

The wholesale acquisition cost (WAC) of Dupixent is approximately $3,564 per month, or roughly $42,768 per year for maintenance dosing at 300 mg every two weeks [7]. Your actual out-of-pocket cost depends on your plan type.

Medicaid Managed Care Members

For members enrolled in Molina's Medicaid managed care product, out-of-pocket costs for Dupixent are minimal. New York Medicaid does not charge copays for most prescription drugs, including specialty medications, for members with income below certain thresholds. Some members may face a nominal copay of $1, $3 per prescription.

Marketplace (Qualified Health Plan) Members

If you enrolled through the NY State of Health exchange, your cost sharing depends on your metal tier. Bronze and silver plans may place Dupixent on a specialty tier with coinsurance of 20 to 40% after the deductible is met. Gold plans typically have lower coinsurance but higher premiums. A $42,768 annual drug cost at 30% coinsurance would mean roughly $12,830 in annual out-of-pocket spending before any manufacturer assistance, though the plan's out-of-pocket maximum caps your total exposure.

Specialty Pharmacy Distribution

Molina typically requires specialty medications like Dupixent to be dispensed through a designated specialty pharmacy. This means you cannot pick up Dupixent at a standard retail pharmacy. Your provider's office will coordinate with the specialty pharmacy, which handles delivery directly to your home or physician's office.

What to Do If Your Dupixent Claim Is Denied

A denial does not mean permanent rejection. According to a 2023 analysis published in JAMA Dermatology, approximately 30% of initial prior authorization requests for biologic therapies in atopic dermatitis are denied, but roughly 75% of those denials are overturned on appeal [8].

Step 1: Understand the Denial Reason

The Explanation of Benefits (EOB) or denial letter from Molina will specify the reason. Common denial reasons include incomplete documentation, failure to meet step therapy requirements, or the prescriber not being a specialist.

Step 2: Peer-to-Peer Review

Your prescribing physician can request a peer-to-peer review with Molina's medical director. This is often the fastest way to resolve a denial. During this call, your doctor can explain why conventional therapies have failed and why Dupixent is medically necessary for your specific case.

Step 3: File a Formal Appeal

Under New York State law, you have 60 days from the date of denial to file an internal appeal. Molina must issue a decision within 30 days for standard appeals or 72 hours for expedited appeals. If the internal appeal is denied, you can request an external review through the New York State Department of Financial Services, which is an independent review by physicians not affiliated with Molina [9].

Step 4: Contact Your State Representative

Dr. Jonathan Silverberg, a dermatologist and atopic dermatitis researcher at George Washington University, has noted: "Patients with moderate-to-severe atopic dermatitis who fail conventional therapy have a clear medical need for targeted biologics. The data supporting dupilumab's efficacy and safety profile is among the strongest in dermatology" [10]. Advocacy organizations such as the National Eczema Association can provide template appeal letters and connect you with patient advocates.

Dupixent Copay and Financial Assistance Programs

Several programs exist to reduce the cost of Dupixent, though eligibility varies by insurance type.

Dupixent MyWay Copay Card

Sanofi and Regeneron's Dupixent MyWay program offers a copay card that can reduce out-of-pocket costs to as low as $0 per month for commercially insured patients. The program covers up to $13,000 per year in copay or coinsurance costs. Patients with government insurance (Medicaid, Medicare, TRICARE) are not eligible for the copay card [11].

Patient Assistance for Uninsured or Underinsured Patients

The Dupixent MyWay program also offers free medication to eligible uninsured patients whose household income falls below 400% of the federal poverty level. Applications are reviewed within 2 to 3 business days.

Foundation Grants

Independent charitable foundations such as the Patient Access Network (PAN) Foundation and the HealthWell Foundation periodically open funding cycles for atopic dermatitis and asthma. These grants can cover copays, premiums, and travel costs related to treatment. Availability fluctuates based on donation cycles, so patients should check regularly.

Alternatives If Dupixent Is Not Covered

If Dupixent coverage is ultimately denied or if you prefer a different treatment pathway, several alternatives exist for moderate-to-severe atopic dermatitis.

JAK Inhibitors

Oral Janus kinase (JAK) inhibitors represent the main alternative class. Abrocitinib (Cibinqo) at 200 mg daily achieved EASI-75 in 63% of patients at 12 weeks in the JADE MONO-2 trial (N=391) [12]. Upadacitinib (Rinvoq) at 30 mg daily achieved EASI-75 in 80% of patients at 16 weeks in the Measure Up 1 trial (N=847) [13]. JAK inhibitors carry boxed warnings for serious infections, malignancy, cardiovascular events, and thrombosis, making them a second-line option for many prescribers.

Tralokinumab (Adbry)

Tralokinumab is another biologic option that specifically targets IL-13. In the ECZTRA 1 and ECZTRA 2 trials (N=1,596 combined), tralokinumab 300 mg every two weeks achieved IGA 0/1 in 16 to 22% of patients at 16 weeks versus 7 to 9% for placebo [14]. While response rates are numerically lower than dupilumab, some patients who do not respond to one biologic may respond to another.

Topical Therapies for Mild-to-Moderate Flares

For patients whose disease does not meet the severity threshold for biologics, newer topical options include ruxolitinib cream (Opzelura), a topical JAK inhibitor approved for mild-to-moderate atopic dermatitis, and tapinarof cream (Vtama), a non-steroidal topical approved for plaque psoriasis and under investigation for atopic dermatitis.

New York State Protections for Specialty Drug Access

New York has some of the strongest patient protections in the country regarding specialty drug access through Medicaid managed care plans.

Continuity of Care Provisions

If you were previously receiving Dupixent under a different plan and transitioned to Molina Healthcare of New York, state law requires a 90-day continuity-of-care period during which your existing prescriptions must be honored without a new prior authorization [15].

External Review Rights

As mentioned above, New York's external review process allows an independent panel of physicians to overturn a plan's denial. The external reviewer's decision is binding on the insurance plan. This protection applies to both Medicaid managed care and marketplace plans.

Timely Access Standards

New York State requires Medicaid managed care organizations to ensure that specialty medications are available within 24 hours when medically necessary. If Molina's designated specialty pharmacy cannot fill the prescription within this window, the plan must allow dispensing at an alternative pharmacy.

Dr. Emma Guttman-Yassky, a professor of dermatology at the Icahn School of Medicine at Mount Sinai, has stated: "The introduction of dupilumab fundamentally changed how we manage moderate-to-severe atopic dermatitis. For patients who have cycled through topical steroids and immunosuppressants without adequate control, it offers a targeted mechanism with a favorable long-term safety profile" [16].

How to Start the Dupixent Coverage Process With Molina

Getting Dupixent approved through your plan follows a predictable sequence. Speed depends largely on how complete the initial submission is.

Schedule a Specialist Visit

Molina Healthcare of New York generally requires the prior authorization request to originate from a dermatologist, allergist, or pulmonologist (depending on the indication). A primary care physician referral may be needed first if your plan requires it.

Gather Your Medical Records

Bring documentation of all prior treatments you have tried, including dates, dosages, duration, and reasons for discontinuation. Photographs showing the severity of your skin condition at its worst can strengthen the prior authorization request.

Ask About the Specialty Pharmacy Network

Confirm with Molina which specialty pharmacy will dispense your Dupixent. Common specialty pharmacy partners for Molina include CVS Specialty, Accredo, and OptumRx Specialty. The specialty pharmacy will coordinate delivery, provide injection training, and handle refill management.

Monitor Renewal Deadlines

Prior authorizations for Dupixent typically last 12 months. Set a reminder 30 days before expiration to initiate the renewal process. Renewal requests generally require updated documentation showing continued medical necessity, such as a recent dermatology visit note confirming ongoing disease activity or a worsening pattern when doses are missed.

The loading dose of Dupixent for adults with atopic dermatitis is 600 mg (two 300 mg injections) on day 1, followed by 300 mg every two weeks thereafter [2].